Punicalagin ameliorates lupus nephritis via inhibition of PAR2
Disclosures: Jessica Burnside: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor, Alnoor Ramji: Nothing to Disclose, Mark Swain: Ipsen: Advisor, Abbott: Advisor, Advanz: Advisor, Novo Nordisk: Advisor, GSK: Advisor, Ipsen: clinical trial research grant support, Novo Nordisk: clinical trial research grant support, Madrigal: clinical trial research grant support, Kowa: clinical trial research grant support, Gilead: clinical trial research grant support, Abbvie: clinical trial research grant support, Merck: clinical trial research grant support, Galectin: clinical trial research grant support, Sahar Saeed: Novo Nordisk: Consultant 1174 STATIN USE WITH CARDIOVASCULAR DISEASE AND ALL-CAUSE MORTALITY IN PATIENTS WITH HYPERTENSION, METABOLIC DYSFUNCTIONASSOCIATED LIVER DISEASE, AND OBESITY: A POPULATION-BASED COHORT STUDY Arunkumar Krishnan Faisal Abaalkhail 1 Aldanah Althwanay 2 Tinsay Woreta 3 Saleh Alqahtani 3 , 1 KING FAISAL SPECIALIST HOSPITAL, 2 University of Maryland Medical Center, 3 Johns Hopkins University School of Medicine Background: Cardiovascular (CV) disease remains the leading global cause of disease burden and mortality among patients with metabolic dysfunctionassociated liver disease (MASLD)
Wir sind berzeugt, dass HSN die beste Wahl fr deine Bestellung ist und deshalb helfen wir dir gern bei all deinen Fragen
Selectivity in Neutralizing Free Radicals One of the most remarkable properties of molecular hydrogen is its selectivity in targeting harmful free radicals while preserving beneficial ones
(2022) 17:e0276879
